

Research & Development – 6 monthly update 5 November 2018

Three wavy lines in blue, green, and pink/magenta colors that span across the bottom of the page.

Agenda Item No: 9.4

Trust Board Report

Meeting Date:	5 th November 2018
Title:	Research & Development – 6 monthly update.
Executive Summary:	<p>This report reflects R&D performance from April 2018 up to end September 2018.</p> <p><u>Key achievements:</u></p> <ul style="list-style-type: none"> • A total of 1353 participants have been recruited into research studies across the Trust to date in 18/19. • 1321 participants were recruited into Portfolio studies*. This is 41% against the annual target set by the CRNWM (3202). 83% against pro rate target. • The R&D Directorate continues to provide alternatives to existing patient care, treatment and choice. • Research activity across a broad range of clinical specialties – not reliant on one study for recruitment. • Feedback from research participants confirms that they value the opportunity to take part in research and that they feel supported and cared for when doing so. • Continued high ratings from external study monitors. • CRN: West Midlands core funding of £1,034,070 allocated – no underspend reported. • The Directorate continues to manage delivery of research in spite of a large reduction in core funding, necessitating ongoing skill mix review and a restructuring of the department. This will threaten research capability in the future <p>*Based on data uploaded to EDGE CPMS as at 15/10/18</p> <p>This report was submitted to the TMC meeting on 26th October 2018.</p>
Action Requested:	Receive and note performance report.
For the attention of the Board	
Assure	<ul style="list-style-type: none"> • This report summarises the performance of the Trust against the NIHR High Level Indicators for research delivery for Quarters 1&2 2018/19. • The report also includes updates with regards to Finance, Governance and Patient and Public Involvement activity within R&D.
Author + Contact Details:	Tel 01902 307999 extn.4218 Email jamescotton@nhs.net Prof. James Cotton, R&D Director.
Links to Trust Strategic Objectives	<ol style="list-style-type: none"> 1. Create a culture of compassion, safety and quality 2. Proactively seek opportunities to develop our services 3. To have an effective and well integrated local health and care system that operates efficiently 4. Attract, retain and develop our staff, and improve employee engagement

	5. Maintain financial health – Appropriate investment to patient services 6. Be in the top 25% of all key performance indicators
Resource Implications:	None

CQC Domains	<p>Safe: patients, staff and the public are protected from abuse and avoidable harm.</p> <p>Effective: care, treatment and support achieves good outcomes, helping people maintain quality of life and is based on the best available evidence.</p> <p>Caring: staff involve and treat everyone with compassion, kindness, dignity and respect.</p> <p>Responsive: services are organised so that they meet people’s needs.</p> <p>Well-led: the leadership, management and governance of the organisation make sure it’s providing high-quality care that’s based around individual needs, that it encourages learning and innovation, and that it promotes an open and fair culture.</p>
Equality and Diversity Impact	None
Risks: BAF/ TRR	n/a
Public or Private:	Public
Other formal bodies involved:	Trust Management Committee
NHS Constitution:	<p>In determining this matter, the Board should have regard to the Core principles contained in the Constitution of:</p> <ul style="list-style-type: none"> • Equality of treatment and access to services • High standards of excellence and professionalism • Service user preferences • Cross community working • Best Value • Accountability through local influence and scrutiny

Report Details							
1	<p>NIHR CRN WM Performance Targets (RWT)</p> <p>1.1 <u>NIHR High Level Objective (HLO) 1 – Increase the number of participants recruited into NIHR CRN Portfolio studies.</u></p> <p>Table (a) provides study recruitment for the Trust into NIHR Portfolio studies during 18/19.</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th style="text-align: center;">No. of participants recruited to date 2018-19</th> <th style="text-align: center;">% Recruitment against Trust target (3202)</th> <th style="text-align: center;">% Recruitment against pro rata target (1601)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">1321</td> <td style="text-align: center;">41%</td> <td style="text-align: center;">83%</td> </tr> </tbody> </table> <p>1.2 <u>NIHR HLO 2 – Increase the proportion of studies recruiting to time and target.</u></p> <p>Of the 16 studies that closed during the first 6 months of 2018/19:</p> <p>(a) 56.3% of commercial studies and</p> <p>(b) 44.4% of non-commercial studies recruited to time and target.</p> <p>The target for this indicator is 80%.</p> <p>1.3 <u>NIHR HLO 3 – Increase the number of commercial contract studies</u></p>	No. of participants recruited to date 2018-19	% Recruitment against Trust target (3202)	% Recruitment against pro rata target (1601)	1321	41%	83%
No. of participants recruited to date 2018-19	% Recruitment against Trust target (3202)	% Recruitment against pro rata target (1601)					
1321	41%	83%					

13 new commercial portfolio studies opened at RWT during the first 6 months of 2018/19.

1.4 NIHR HLO 4 – Proportion of studies achieving set up at site within 40 calendar days

36% of studies were set-up at RWT within 40 days during Qtrs 1&2 2018/19.

The target for this indicator is 80%.

1.5 NIHR HLO 5 – Proportion of studies achieving first participant recruited within 30 days of date site confirmed

Of the 15 new studies opened and recruited into this year to date,

(a) 57% of commercial studies and

(b) 100% of non-commercial studies recruited first participant within 30 days.

The target for this indicator is 80%.

2 Overall Research Performance

2.1 Overall research recruitment and activity across the Trust for Qtrs 1&2 2018/19 is given in table (b) below and further detailed in Appendix 1.

Table (b) – All Study Recruitment

Study Category	Recruitment 18/19
Portfolio – non-commercial	1108
Portfolio – commercial	213
Non-commercial (other)	32
Commercial (direct)	0
Total	1353

3 Finance

3.1 2018/19 Research Funding

The R&D Directorate has received the following funding to support Trust research activity during 18/19:

- *CRN: West Midlands Allocation*
 - Core Funding £1,034,070
 - Strategic Funding £64,496

This represents a £54,425 decrease in core funding from 17/18.

All funding has been allocated, with a breakeven position reported at Qtr 2.

- *Commercial Research Income – Quarter 1*
 - Invoices based on contracted research activity £184,223

This amount is slightly higher (£47k) than for Qtr 1 2017/18. Data for Qtr 2 is not yet available.

There are currently approx. £300k in bad debts for completed research activity. One study

accounts for £190k of this debt and is being considered by the Trusts legal team. The value of these debts are resulting in significant cost pressures within the R&D accounts.

4 Patient & Public Involvement

4.1 Publicity and Communication

- A dedicated twitter account, managed by the Trust communications team, for research at RWT went live in early 2018: [@RWTResearch](#)
- A growing number of individuals, research organisations and sponsors are following this account to hear about innovative research taking place at RWT.

5 Governance

As part of our on-going commitment to quality and performance, the R&D Directorate continues to review and support quality assurance in line with European and UK regulator standards.

5.1 External Inspections.

- For the period of 1st April to 30th September 2018, 199 monitoring site visits have been conducted by study sponsors.
- No external inspections for regulatory purposes relating to research activities were undertaken during Qtrs 1&2 2018/19.

5.2 Annual Audit Programme

9 audits were completed during the year, as per audit plan.

	Total
Delegation Log Audit	1
Consent Audit	0
External Access to Clinical Portal	6
Study Site File Audits	1
Out of Hours Process	0
Monitor Reports Audit	1
	9

Audit results are reported to the R&D Directorate Governance meeting and action plans agreed as necessary.

6 Awards and Commendations

The CRN WM held their Annual Network Awards on 4th October and RWT was recognised and rewarded for its research achievements.

The CRN received over 60 nominations for the awards and RWT researchers were shortlisted in 4 categories. The results were:

- The Cardiovascular Research Team – Winners of the **Team of the Year**.
- Lyndsay Bibb and the REACT study team – Highly commended in the **Collaboration in Research** category.
- Marie Green – Highly commended in the **Creative Recruitment** category.
- Professor Matt Brookes – Highly Commended in the Investigator of the Year

category.

The Trust has also been recognised by commercial and non-commercial research sponsors for ranking highest in the UK for recruitment into studies in the following specialties:

- Oncology
- Rheumatology
- Paediatrics

Appendices

1	Trust Research Activity 2018/19
---	---------------------------------

Appendix 1 – Trust Research Activity 2018/19

April 18 – September 18	KPI's									
	Research Active	No. of NIHR Portfolio Trials	Accruals (NIHR Portfolio)	No. of open Non-Portfolio trials	Accruals (Non Portfolio)	No. of own account trials	Active PI's	Active CI's in dept	Linked Research Nurses	Linked CTAs/ AHP's
Emergency & Medical Division										
Rehabilitation & Ambulatory Medical Group	Y	5	20	3	0	0	2	0	3	1
Medical Group										
Respiratory	Y	2	6	3	0	1	2	0	1	1
Gastroenterology & Hepatology	Y	18	58	5	2	4	6	3	2	1
Diabetes	Y	4	18	0	0	2	3	2	1	1
Renal	Y	8	11	5	0	0	4	0	1	1
Emergency Services Group	Y	1	92	0	0	0	2	0	0	0
Oncology & Haematology Group	Y	27	28	10	0	1	12	1	11	4
Total		65	233	26	2	8	31	6	19	9
Surgical Division										
Pathology/Clinical Chemistry	Y	1	131*	2	0	2	2	2	0	0
Critical Care Services Group	Y	0	0	2	0	0	1	0	1	1
Cardiology/Cardiothoracic Service Group	Y	9	240	4	0	6	7	5	5	2
Surgical Services Group										
General Surgery	Y	1	3	0	0	1	2	2	4	0
Orthopaedics	N									
Urology	Y	3	4	0	0	0	2	0	3	1
Ophthalmology/Head and Neck Services Group	Y	3	10	1	30	2	2	2	3	1
Obs & Gynae	Y	7	166	3	0	1	1	1	2	1
Total		24	554	12	30	12	17	12	18	6
Community, Childrens & Support Services Division										
Adult Community Services	N									
Sexual Health	Y	2	5	0	0	0	1	0	1	1
Radiology	Y									
Therapies & Pharmacies Group	Y	0	0	1	0	0	0	0	0	0
Nutrition & Dietetics	N									
Rheumatology	Y	12	172	1	0	0	7	1	8	3
Dermatology	Y	2	29	1	0	0	2	0	3	1
Children's Services	Y	13	91	3	0	1	5	1	3	1
Total		29	297	6	0	1	15	2	15	6
Corporate / Health Service Delivery	Y	2	176	10	0	2	2	0	0	0
Genetics	Y	1	61	0	0	0	0	0	0	0
Total		3	237	10	0	2	2	0	0	0
Total		121	1321	48	32	23	65	20	52	21

*Trust sponsored Portfolio study involving Cardiovascular and Clinical Chemistry – Chief Investigator Prof R. Gama